Comprehensive Diagnostic Profile (20+7)
A broad veterinary chemistry panel for liver, gallbladder, renal, pancreatic, metabolic, electrolyte, and acid-base assessment, combining 20 measured analytes with 7 calculated indicators in one run.
High-value clinical uses
Useful in sick-patient triage, wellness screening, pre-anesthetic workups, dehydration and electrolyte assessment, renal monitoring, hepatobiliary investigation, pancreatitis suspicion, and follow-up of systemic illness.
Core coverage
Protein profile, hepatic injury and cholestasis markers, bile acid testing, renal markers, pancreatic enzymes, glucose and cholesterol, electrolytes, minerals, and total CO2.
Platform workflow
Designed for the Celercare V / Pointcare V chemistry analyzer family using a fixed 100 μL sample input and barcode-based disc calibration.
What this panel is for
The Comprehensive Diagnostic Profile (20+7) is intended for in vitro quantitative determination of total protein, albumin, total bilirubin, ALT, creatinine, amylase, glucose, total cholesterol, potassium, sodium, chloride, calcium, phosphorus, AST, total bile acid, GGT, total carbon dioxide, BUN, ALP, and lipase on the Celercare V or Pointcare V chemistry analyzer. In practical veterinary use, this profile helps investigate liver and gallbladder disease, glucose and lipid metabolism disorders, water and salt imbalance, pancreatic disease, urinary system disease, and broader internal medicine presentations.
Measured test items (20)
Calculation items (7)
*Calculated indicators are pattern-support tools. They improve screening value but should not be treated as stand-alone diagnoses.
Sample, workflow, and handling
Specimen
Lithium heparin plasma or serum. Use only lithium heparin evacuated collection tubes for plasma samples.
Sample volume
100 μL sample input per test disc.
Timing
Run the sample within 60 minutes of collection/handling workflow and start the test within 10 minutes after transferring the sample to the disc.
Disc storage
Store sealed reagent discs at 2–8°C. Do not expose opened or unopened discs to direct sunlight or temperatures above 32°C. Do not use discs from damaged pouches.
- Glucose: fasting for at least 12 hours improves accuracy where clinically appropriate; uncentrifuged room-temperature samples can show a measurable glucose drop over time.
- Bilirubin: protect samples from light because bilirubin can degrade and produce falsely lower results.
- Potassium: for the same sample, potassium in anticoagulated plasma may read about 0.2–0.5 mmol/L lower than in serum.
Clinical interpretation by analyte group
Protein profile
TP, ALB, GLO, ALB/GLO help evaluate hydration, protein loss, inflammatory stimulation, and hepatic synthetic support. High TP with high albumin commonly fits hemoconcentration. Low albumin raises concern for loss, reduced production, or dilution. High globulin pushes you toward inflammation, antigenic stimulation, or gammopathy.
Hepatic injury, cholestasis, and hepatic function
ALT and AST are injury/leakage markers. ALP and GGT support cholestatic or biliary patterns. TBIL reflects bilirubin burden from hemolysis, impaired hepatic handling, or cholestasis. TBA is especially valuable when asking whether hepatic function or portal circulation is impaired.
Renal and hydration assessment
CRE, BUN, and BUN/CRE help screen filtration problems and prerenal trends. A disproportionate BUN rise can fit dehydration, GI bleeding, or protein catabolism. Creatinine is the stronger filtration marker but can be lowered by low muscle mass.
Pancreas, glucose, and lipids
AMY and LPS can support pancreatic disease suspicion, especially when paired with compatible clinical signs and imaging. GLU evaluates dysglycemia and critical illness. CHOL helps with cholestatic patterns, endocrine disease screening, and lipid metabolism abnormalities.
Electrolytes and acid-base
Na+, K+, Cl-, tCO2, and AG are central to fluid balance and metabolic acid-base interpretation. Sodium reflects water balance, potassium carries major arrhythmia risk if severely abnormal, chloride sharpens acid-base interpretation, tCO2 approximates the metabolic bicarbonate component, and AG estimates unmeasured anions.
Minerals
Ca, P, and Ca×P help assess renal compromise, parathyroid/vitamin D disorders, tissue mineralization risk, and some neoplastic or nutritional disorders. Marked hyperphosphatemia with high calcium deserves extra attention.
Quick high / low interpretation guide
| Analyte | Main intent of use | When high may suggest | When low may suggest / key notes |
|---|---|---|---|
| TP | Hydration and protein screening | Dehydration, hyperglobulinemia | Protein loss, hemorrhage, dilution; interpret with ALB and GLO |
| ALB | Oncotic support, hepatic synthesis, loss | Usually dehydration | Protein loss, reduced synthesis, dilution |
| GLO* | Inflammatory and immune protein estimate | Inflammation, chronic antigenic stimulation, gammopathy | Protein loss or low globulin states |
| ALT | Hepatocellular leakage/injury | Hepatocellular injury | Usually not clinically useful when low |
| AST | Liver or muscle injury support | Hepatic or muscular injury | Use with ALT and clinical context; low values rarely matter |
| ALP | Cholestatic response | Cholestasis, biliary disease, steroid/drug induction in some species | Low values usually not significant |
| GGT | Biliary epithelium / cholestasis | Cholestatic or biliary disease | Low values usually not significant |
| TBIL | Bilirubin burden | Cholestasis, hemolysis, impaired hepatic handling | Protect sample from light |
| TBA | Hepatic function / portal circulation | Hepatic insufficiency, shunting, cholestasis | Less useful for function assessment once marked cholestasis is already present |
| CRE | Filtration marker | Decreased GFR, renal/postrenal causes | May be lower with low muscle mass |
| BUN | Renal and protein metabolism screening | Prerenal azotemia, renal disease, GI bleeding, catabolism | Low protein intake, hepatic dysfunction, dilution |
| AMY | Pancreatic support marker | Pancreatic disease, renal retention, GI disease | Low values rarely useful |
| LPS | Pancreatic support marker | Pancreatitis suspicion, pancreatic injury | Interpret with signs and imaging; do not use alone |
| GLU | Metabolic and emergency screening | Stress hyperglycemia, diabetes mellitus, endocrine disease | Sepsis, insulin excess, severe hepatic dysfunction, delayed sample separation |
| CHOL | Lipid and cholestatic screening | Cholestasis, endocrine disease, nephrotic states | Malabsorption, severe hepatic dysfunction, shunting |
| K+ | Electrolyte and arrhythmia risk | Renal failure, urinary obstruction, Addisonian pattern, hemolysis/artifact | GI loss, renal loss, alkalosis, insulin shifts |
| Na+ | Water balance | Water deficit / hypertonic states | Dilutional states, sodium loss, endocrine disease |
| Cl- | Acid-base support | Hyperchloremic acidosis pattern | Vomiting / chloride loss, alkalosis pattern |
| Ca | Mineral balance | Hypercalcemia, renal or endocrine disease, neoplasia | Hypoalbuminemia, true hypocalcemia, critical illness |
| P | Renal/mineral screening | Reduced excretion, growth, cell breakdown, vitamin D issues | Refeeding issues, losses, endocrine causes |
| tCO2 | Metabolic acid-base estimate | Metabolic alkalosis or compensation patterns | Metabolic acidosis support |
| ALB/GLO* | Protein pattern balance | Relative globulin depletion | Relative globulin excess or albumin loss |
| AST/ALT* | Pattern clue only | Can suggest more extrahepatic/muscle contribution when AST is disproportionately high | Not diagnostic alone |
| BUN/CRE* | Prerenal vs disproportion clues | BUN disproportionately high in dehydration/GI bleeding/catabolism | Lower ratio may fit low urea production or relatively higher creatinine |
| K+/Na+* | Electrolyte ratio flag | Higher K relative to Na heightens concern for Addisonian-style pattern or severe urinary/renal disease | Use with actual electrolytes, hydration, and clinical signs |
| Ca×P* | Mineralization risk screen | Rising product increases concern for soft tissue mineralization risk | Context-dependent, not a stand-alone diagnosis |
| AG* | Unmeasured anion estimate | High-anion-gap metabolic acidosis, lactate/ketones/toxins | Low albumin can blunt AG |
Pattern-based diagnostic scenarios
1) Dehydration / prerenal trend
TP and albumin high-normal or increased, BUN rising more than creatinine, sodium/chloride may shift with water loss. Confirm with history, exam, urine concentration, and response to fluids.
2) Hepatocellular injury
ALT and AST increased, bilirubin may or may not rise. This points toward hepatocyte injury or leakage, but not automatically liver failure.
3) Cholestatic / biliary disease
ALP and GGT increased, often with bilirubin and cholesterol increases. TBA may also rise, but once cholestasis is present it is less specific for pure function assessment.
4) Hepatic insufficiency or portal vascular problem
High TBA with low BUN, low cholesterol, and possibly low albumin or glucose can support reduced hepatic function or altered portal circulation.
5) Renal compromise / azotemia
Creatinine and BUN rise together; phosphorus may also rise. Pair with urinalysis and imaging to distinguish prerenal, renal, and postrenal causes.
6) Pancreatic disease suspicion
Amylase and lipase increased with vomiting, abdominal pain, anorexia, or compatible imaging findings raise suspicion for pancreatitis, although enzyme changes alone do not confirm it.
7) Addisonian-style electrolyte concern
Potassium high with sodium low and a rising K+/Na+ relationship should trigger concern for hypoadrenocorticism or another severe electrolyte-shifting disorder. Confirm with proper endocrine testing.
8) Hyperchloremic metabolic acidosis
Low tCO2 with relatively high chloride suggests a normal-anion-gap metabolic acidosis pattern, often seen with bicarbonate loss or certain fluid/electrolyte disturbances.
9) High-anion-gap metabolic acidosis
Low tCO2 with increased AG points toward unmeasured acids such as lactate or ketones and fits more severe perfusion or metabolic disturbances.
10) Mineralization risk
When calcium and phosphorus are both high, the Ca×P product rises and soft tissue mineralization risk becomes more concerning, especially in renal disease or vitamin D-related disorders.
Reference intervals (guideline values from the 20+7 IFU)
These intervals are provided by the IFU as guidelines only. Each laboratory or institution should establish intervals for its own patient population and specimen type.
| Analyte | Dog | Cat |
|---|---|---|
| TP | 5.2–8.2 g/dL | 5.4–8.9 g/dL |
| ALB | 2.2–4.4 g/dL | 2.2–4.5 g/dL |
| ALT | 10–140 U/L | 8.2–123 U/L |
| ALP | 20–150 U/L | 10–90 U/L |
| TBIL | 0.1–0.9 mg/dL | 0.1–0.9 mg/dL |
| CRE | 0.3–1.7 mg/dL | 0.3–2.5 mg/dL |
| BUN | 7–32 mg/dL | 10–43 mg/dL |
| GLU | 70–143 mg/dL | 74–159 mg/dL |
| CHOL | 110–320 mg/dL | 65–225 mg/dL |
| AMY | 200–1800 U/L | 200–1800 U/L |
| K+ | 3.7–5.8 mmol/L | 3.7–5.8 mmol/L |
| Na+ | 138–160 mmol/L | 142–164 mmol/L |
| Cl- | 106–130 mmol/L | 100–126 mmol/L |
| Ca | 7.9–11.8 mg/dL | 7.8–11.8 mg/dL |
| P | 2.5–6.8 mg/dL | 3.1–8.5 mg/dL |
| GGT | 0–7 U/L | 0–2 U/L |
| TBA | 0–20 μmol/L | 0–15 μmol/L |
| AST | 8.9–55 U/L | 9.2–60 U/L |
| tCO2 | 12–27 mmol/L | 15–24 mmol/L |
| LPS | 0–258 U/L | 0–143 U/L |
Interference, reporting, and performance notes
Sample flags
Hemolysis, lipemia, and icterus can alter reported values. The analyzer suppresses results affected by more than 10% interference and prints HEM, LIP, or ICT in place of the result.
Unexpected potassium
Because potassium is measured using a coupled PK/LDH assay, marked muscle injury or very high CK by another method can contribute to unexpectedly high potassium results that should be verified by another methodology.
Range and rerun caution
If a result exceeds the assay range, confirm it using another approved method or a referral laboratory. Do not dilute the sample and rerun it on the analyzer.
Performance summary
The IFU provides analyte-specific accuracy, within-batch precision, inter-batch precision, and dynamic ranges. This supports use for screening and follow-up, but all results still require clinical correlation.
Why this profile is valuable
This panel gives strong day-to-day diagnostic reach in a single run: protein balance, hepatobiliary markers, bile acid support, azotemia screening, pancreatic support enzymes, electrolyte and acid-base clues, and mineral balance. It is broad enough for first-line workups yet structured enough to support trend monitoring in internal medicine, emergency, and hospitalized patients.
References
Primary product / IFU reference
- Tianjin MNCHIP Technologies Co., Ltd. Celercare V / Pointcare V chemistry analyzer IFU. Used for analyte list, instrument compatibility, sample requirements, storage, interference notes, dynamic ranges, and guideline reference intervals.